Drug
PX-866
PX-866 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 83.3%.
Total Trials
6
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
83.3%
Based on 5 completed trials
Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
1(17%)
Phase Distribution
Ph phase_1
4
67%
Ph phase_2
2
33%
Phase Distribution
4
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
83.3%
5 of 6 finished
Non-Completion Rate
16.7%
1 ended early
Currently Active
0
trials recruiting
Total Trials
6
all time
Status Distribution
Completed(5)
Terminated(1)
Detailed Status
Completed5
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
0
Success Rate
83.3%
Most Advanced
Phase 2
Trials by Phase
Phase 14 (66.7%)
Phase 22 (33.3%)
Trials by Status
completed583%
terminated117%
Recent Activity
0 active trials
Showing 5 of 6
completedphase_2
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
NCT01331083
completedphase_2
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
NCT01259869
completedphase_1
Phase I Trial of Oral PX-866
NCT00726583
completedphase_1
Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers
NCT01408316
completedphase_1
Study of PX-866 and Docetaxel in Solid Tumors
NCT01204099
Clinical Trials (6)
Showing 6 of 6 trials
NCT01331083Phase 2
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
NCT01259869Phase 2
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
NCT00726583Phase 1
Phase I Trial of Oral PX-866
NCT01408316Phase 1
Study of the Pharmacokinetics and Pharmacodynamics of Crystalline PX-866 Tablets and Amorphous PX-866 Capsules in Healthy Volunteers
NCT01204099Phase 1
Study of PX-866 and Docetaxel in Solid Tumors
NCT01616199Phase 1
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6